PHASE I SAFETY/FEASIBILITY: GENETICALLY MODIFIED AUTOLOGOUS T CELLS IN LYMPHOMA

I 期安全性/可行性:转基因自体 T 细胞治疗淋巴瘤

基本信息

  • 批准号:
    7603429
  • 负责人:
  • 金额:
    $ 0.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-04-01 至 2007-09-16
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Relapsed B cell lymphomas are incurable with conventional therapies except stem cell transplantation, a toxic treatment modality which salvages only 20-50% of patients with recurrent disease. Innovative new treatment approaches are therefore clearly necessary. This phase I study will evaluate the feasibility, safety, toxicity, and efficacy of using gene therapy to treat patients with relapsed or refractory mantle cell or indolent non-Hodgkin's lymphomas. This clinical trial uses genetically modified immune cells to try to improve the body's immune system to fight lymphoma. Immune cells will be taken from the patient's body through leukapheresis, and then genetically modified and expanded to large numbers in a laboratory before being reinfused to the patient in three doses. Twelve people will take part in the study. The first three people who take part received immune cell infusions alone, and the remainder will receive the same treatment, plus the drug interleukin 2 (IL-2) to stimulate the immune cells to grow. In some patients, the second or third dose of cells may be labeled with Indium-111 for assessment of in vivo trafficking The study will examine the safety and toxicity of this approach, how a patient's lymphoma responds to the genetically modified immune cells, how long these cells remain in the body, where the cells travel in the body, and whether the body develops an immune response to these cells.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Oliver W. Press其他文献

Phytohemagglutinin-induced differentiation and blastogenesis of precursor T cells from mouse bone marrow
植物血凝素诱导小鼠骨髓前体 T 细胞的分化和胚细胞发生
  • DOI:
  • 发表时间:
    1977
  • 期刊:
  • 影响因子:
    15.3
  • 作者:
    Oliver W. Press;C. Rosse;James Clagett
  • 通讯作者:
    James Clagett
Megadose sup90/supY-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma
大剂量 sup90/supY-伊布妥昔单抗替伊莫单抗在异基因移植前对侵袭性大 B 细胞淋巴瘤有效
  • DOI:
    10.1182/bloodadvances.2021005056
  • 发表时间:
    2022-01-11
  • 期刊:
  • 影响因子:
    7.100
  • 作者:
    Victor A. Chow;Ryan D. Cassaday;Theodore A. Gooley;Stephen D. Smith;Brenda M. Sandmaier;Damian J. Green;Johnnie J. Orozco;Sherilyn A. Tuazon;Manuela Matesan;Darrell R. Fisher;David G. Maloney;Oliver W. Press;Ajay K. Gopal
  • 通讯作者:
    Ajay K. Gopal
Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma.
物理学从业者:放射性标记单克隆抗体在 B 细胞非霍奇金淋巴瘤中的应用。
Radioimmunotherapy-Augmented Nonmyeloablative Allogeneic Transplantation Improves Outcomes for Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Results of an Adjusted Cohort Analysis
  • DOI:
    10.1016/j.bbmt.2013.12.087
  • 发表时间:
    2014-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Ryan D. Cassaday;Barry E. Storer;Mohamed L. Sorror;Brenda M. Sandmaier;Katherine A. Guthrie;Lacey M. Hedin;Jennifer E. Roden;Joseph G. Rajendran;John M. Pagel;David G. Maloney;Rainer F. Storb;Oliver W. Press;Ajay K. Gopal
  • 通讯作者:
    Ajay K. Gopal
Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211
  • DOI:
    10.1016/j.jmir.2019.11.017
  • 发表时间:
    2019-12-01
  • 期刊:
  • 影响因子:
  • 作者:
    Yawen Li;Ming-Kuan Chyan;Donald K. Hamlin;Damian J. Green;Oliver W. Press;D. Scott Wilbur
  • 通讯作者:
    D. Scott Wilbur

Oliver W. Press的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Oliver W. Press', 18)}}的其他基金

CD38 Pretargeted Radioimmunotherapy for Myeloma
CD38 骨髓瘤预靶向放射免疫治疗
  • 批准号:
    8185529
  • 财政年份:
    2011
  • 资助金额:
    $ 0.35万
  • 项目类别:
CD38 Pretargeted Radioimmunotherapy for Myeloma
CD38 骨髓瘤预靶向放射免疫治疗
  • 批准号:
    8291997
  • 财政年份:
    2011
  • 资助金额:
    $ 0.35万
  • 项目类别:
CD38 Pretargeted Radioimmunotherapy for Myeloma
CD38 骨髓瘤预靶向放射免疫治疗
  • 批准号:
    8657898
  • 财政年份:
    2011
  • 资助金额:
    $ 0.35万
  • 项目类别:
CD38 Pretargeted Radioimmunotherapy for Myeloma
CD38 骨髓瘤预靶向放射免疫治疗
  • 批准号:
    8465138
  • 财政年份:
    2011
  • 资助金额:
    $ 0.35万
  • 项目类别:
PRETARGETED ANTI-CD45 RADIOIMMUNOTHERAPY STUDIES IN MACAQUES
猕猴中的预先靶向抗 CD45 放射免疫治疗研究
  • 批准号:
    8172763
  • 财政年份:
    2010
  • 资助金额:
    $ 0.35万
  • 项目类别:
RADIOIMMUNOTHERAPY AND EXTRACORPOREAL ADSORPTION THERAPY STUDIES IN MACAQUES
猕猴的放射免疫治疗和体外吸附治疗研究
  • 批准号:
    8172764
  • 财政年份:
    2010
  • 资助金额:
    $ 0.35万
  • 项目类别:
Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
使用新型放射免疫进行骨髓移植治疗血液系统恶性肿瘤
  • 批准号:
    8591380
  • 财政年份:
    2010
  • 资助金额:
    $ 0.35万
  • 项目类别:
Bispecific Antibody Engineering for AML RIT
AML RIT 的双特异性抗体工程
  • 批准号:
    8469739
  • 财政年份:
    2009
  • 资助金额:
    $ 0.35万
  • 项目类别:
PRETARGETED ANTI-CD45 RADIOIMMUNOTHERAPY STUDIES IN MACAQUES
猕猴中的预先靶向抗 CD45 放射免疫治疗研究
  • 批准号:
    7958870
  • 财政年份:
    2009
  • 资助金额:
    $ 0.35万
  • 项目类别:
RADIOIMMUNOTHERAPY AND EXTRACORPOREAL ADSORPTION THERAPY STUDIES IN MACAQUES
猕猴的放射免疫治疗和体外吸附治疗研究
  • 批准号:
    7958871
  • 财政年份:
    2009
  • 资助金额:
    $ 0.35万
  • 项目类别:

相似海外基金

Roles of immune cells derived from clonal hematopoiesis in B-cell lymphomas
克隆造血来源的免疫细胞在 B 细胞淋巴瘤中的作用
  • 批准号:
    24K19213
  • 财政年份:
    2024
  • 资助金额:
    $ 0.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identification of novel biomarkers for EBV-associated B-cell lymphomas arising in the oral cavity
口腔中出现的 EBV 相关 B 细胞淋巴瘤的新型生物标志物的鉴定
  • 批准号:
    23K15982
  • 财政年份:
    2023
  • 资助金额:
    $ 0.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
  • 批准号:
    10606730
  • 财政年份:
    2023
  • 资助金额:
    $ 0.35万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10566833
  • 财政年份:
    2023
  • 资助金额:
    $ 0.35万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10987699
  • 财政年份:
    2023
  • 资助金额:
    $ 0.35万
  • 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
  • 批准号:
    10541285
  • 财政年份:
    2022
  • 资助金额:
    $ 0.35万
  • 项目类别:
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
  • 批准号:
    10540952
  • 财政年份:
    2022
  • 资助金额:
    $ 0.35万
  • 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
  • 批准号:
    10703446
  • 财政年份:
    2022
  • 资助金额:
    $ 0.35万
  • 项目类别:
Therapeutic potential of novel antibody-oligonucleotide conjugate for intractable B-cell lymphomas
新型抗体-寡核苷酸缀合物治疗难治性 B 细胞淋巴瘤的潜力
  • 批准号:
    22K08497
  • 财政年份:
    2022
  • 资助金额:
    $ 0.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
  • 批准号:
    10707312
  • 财政年份:
    2022
  • 资助金额:
    $ 0.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了